<b>AI TRADING BOT - POST-MARKET REPORT</b>
<b>Wednesday, September 24, 2025</b>
<b>09:30 AM ET</b>
=============================================

<b>DUAL-STRATEGY PORTFOLIO OVERVIEW</b>
Total Portfolio Value: <b>$205,457.25</b>
Total Unrealized P&L: <b>$+5,199.73</b>
Total Return: <b>+2.60%</b>
Active Positions: <b>20</b>
Strategy Split: <b>DEE 49% | SHORGAN 51%</b>

<b>==== DEE-BOT (Beta-Neutral S&P 100) ====</b>
Strategy: <b>Beta-Neutral S&P 100</b>
Portfolio Value: <b>$100,118.84</b>
Position Value: <b>$18,307.89</b>
Cash Available: <b>$81,810.95</b>
Unrealized P&L: <b>$+118.84</b>
Positions: <b>3 large-caps</b>
Portfolio Beta: <b>~1.0 (target)</b>
Best: <b>PG (+1.06%)</b>
Worst: <b>KO (+0.42%)</b>

<b>==== SHORGAN-BOT (Catalyst Trading) ====</b>
Strategy: <b>Catalyst Trading</b>
Portfolio Value: <b>$105,338.41</b>
Position Value: <b>$98,305.44</b>
Cash Available: <b>$7,032.97</b>
Unrealized P&L: <b>$+5,080.89</b>
Positions: <b>17 catalyst plays</b>
Focus: <b>FDA events, earnings, momentum</b>
Best: <b>RGTI (+22.73%)</b>
Worst: <b>KSS (-7.37%)</b>

<b>UPCOMING CATALYSTS</b>
<b>Tomorrow (Sept 17):</b> CBRL Earnings
   - 81 shares positioned for potential squeeze
<b>Thursday (Sept 19):</b> INCY FDA Decision
   - 61 shares positioned for binary approval

<b>RISK ASSESSMENT</b>
Capital Deployed: <b>$116,613.33</b>
Capital Exposure: <b>58.3%</b>
<b>CONTROLLED EXPOSURE</b>

<b>SYSTEM STATUS</b>
Multi-Agent Analysis: <b>ACTIVE</b>
Risk Management: <b>ACTIVE</b>
Stop Losses: <b>PROTECTED</b>
Portfolio Monitoring: <b>24/7</b>

=============================================
<b>Next Report:</b> Tomorrow 4:15 PM ET
<b>Status:</b> FULLY OPERATIONAL